Alexander J Sarissa Capital... Net Worth

Insiders trading at Regulus Therapeutics Inc

Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.

What does Regulus Therapeutics Inc do?

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Regulus Therapeutics Inc executives and stock owners

Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Hagan,
  President, Chief Executive Officer, Director
• Joseph P. Hagan M.B.A.,
  Pres, CEO & Director
• Christopher Aker,
  Senior Vice President, General Counsel
• Christopher Ray Aker J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Crispina Calsada,
  Chief Financial Officer
• Crispina Calsada,
  Chief Financial Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Pascale Witz,
  Independent Director
• Simos Simeonidis,
  Independent Director
• Hugh Rosen,
  Independent Director
• William Rastetter,
  Independent Director
• Jake Nunn,
  Independent Director
• Kathryn Collier,
  Independent Director
• David Baltimore,
  Independent Director
• Denis Drygin,
  Chief Scientific Officer
• Firuz Shakoori,
  Head of CMC
• Turner Jenkins,
  Sr. Director of Corp. Devel.
• Dr. Denis Drygin Ph.D.,
  Chief Scientific Officer
• Daniel J. Penksa,
  Controller & Principal Accounting Officer
• Jason Raleigh Nunn,
  
• Daniel R. Chevallard,
  Chief Financial Officer
• Paul C Grint,
  President & CEO
• Douglas E Williams,
  Director
• Mark Albert Deeg,
  Chief Medical Officer
• Pharmaceuticals, Inc. Alnylam,
  10% owner
• Mark G Foletta,
  Director
• Timothy Michael Wright,
  Chief R & D Officer
• Alexander J Sarissa Capital...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• David Leslie Szekeres,
  Chief Business Officer & GC
• Paul Edward Walker,
  
• Peter J Barris,
  10% owner
• Anthony A. Jr. Florence,
  
• Scott D Sandell,
  
• David M Mott,
  10% owner
• Mohamad Makhzoumi,
  
• Equity Opportunities V, Llc...,
  
• Ali Behbahani,
  
• Neil W Gibson,
  Chief Scientific Officer
• Pharmaceuticals Incparshall...,
  
• Kleanthis G Xanthopoulos,
  President and CEO
• Pharmaceuticals Inc Ionis,
  10% owner
• Bruce L A Carter,
  Director
• Barry E Greene,
  Director
• Sanofi,
  10% owner
• B Lynne Parshall,
  Director
• Stanley T Crooke,
  Director
• John Maraganore,
  Director
• Garry E Menzel,
  COO & Executive VP, Finance
• Forest Baskett,
  
• Carmen Chang,
  
• Joshua Makower,
  
• Peter W. Sonsini,
  
• Capital Offshore Master Fun...,
  10% owner
• Alice Shih Hou Baltimore Da...,
  
• Alice Shih Hou Huang,
  
• Preston Klassen,
  President & Head of R & D